![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
P Aduma, MC Connelly, RV Srinivas and A Fridland
Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
The acyclic nucleoside phosphonates (S)-1-(3-hydroxy-2- phosphonylmethoxypropyl)cytosine (HPMPC), (S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine (HPMPA), and 9-(2- phosphonylmethoxyethyl)adenine (PMEA) inhibited herpes simplex virus-1 replication in Vero cells, and the IC50 values ranged from 4 microM (for HPMPC and HPMPA) to 40 microM (for PMEA). Pretreatment of cells with HPMPC for 12-24 hr induced an effective antiviral state, and the cells maintained this antiviral state for > 7 days. In contrast, much larger amounts (approximately 2.5-5 x IC50 doses) of PMEA or HPMPA were required to establish an antiviral state, which lasted for only approximately 24 or 72 hr, respectively. A 12-hr treatment of the cells with the phosphonates was required for the establishment of optimal antiviral activity; surprisingly, longer durations of exposure to PMEA (but not HPMPA or HPMPC) resulted in diminished antiviral effect. We investigated the metabolism of PMEA and HPMPC to determine the cellular basis for these differences. The cellular uptake of HPMPC was approximately 8-fold greater than that of PMEA. The levels of the PMEA metabolites PMEA monophosphate and PMEA diphosphate increased for approximately 12 hr and plateaued thereafter. PMEA and its metabolites were cleared from the cells with a half-life of 4.9 hr. In contrast, the HPMPC metabolites HPMPC monophosphate (HPMPCp) and HPMPC diphosphate (HPMPCpp) accumulated throughout the 24-hr study period and, at equimolar drug concentrations (25 microM), reached intracellular levels approximately 2-3-fold greater than those of the PMEA metabolites. HPMPC also differed from PMEA in its capacity to generate a phosphodiester metabolite (HMPCp-choline), which was a predominant metabolite in HPMPC-treated cells. In addition, the rates of disappearance of intracellular metabolites of the two drugs were significantly different. Thus, the decay of HPMPCpp was quite slow and biphasic (t1/2 = 24 and 65 hr) and that of HMPCp-choline was monophasic (t1/2 = 87 hr). Together, these factors can explain the differing antiviral potencies seen with PMEA and HPMPC. The possible role of the choline adduct in the expression of antiviral activity of the drug remains to be elucidated, but the adduct may serve as an intracellular store for the long term maintenance of active HPMPCpp in cells. The results also highlight the extent of diversity in the cellular pharmacology and antiviral activities of the acyclic nucleoside phosphonates.
This article has been cited by other articles:
|
|
 |
|
  K. A. Aldern, S. L. Ciesla, K. L. Winegarden, and K. Y. Hostetler Increased Antiviral Activity of 1-O-Hexadecyloxypropyl-[2-14C]cidofovir in MRC-5 Human Lung Fibroblasts Is Explained by Unique Cellular Uptake and Metabolism Mol. Pharmacol., March 1, 2003; 63(3): 678 - 681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Balzarini, C. Pannecouque, E. De Clercq, S. Aquaro, C.-F. Perno, H. Egberink, and A. Holy Antiretrovirus Activity of a Novel Class of Acyclic Pyrimidine Nucleoside Phosphonates Antimicrob. Agents Chemother., July 1, 2002; 46(7): 2185 - 2193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Bijsterbosch, C. Ying, R. L. A. de Vrueh, E. de Clercq, E. A. L. Biessen, J. Neyts, and T. J. C. van Berkel Carrier-Mediated Delivery Improves the Efficacy of 9-(2-Phosphonylmethoxyethyl)Adenine against Hepatitis B Virus Mol. Pharmacol., September 1, 2001; 60(3): 521 - 527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Liekens, J. Neyts, E. De Clercq, E. Verbeken, D. Ribatti, and M. Presta Inhibition of Fibroblast Growth Factor-2-induced Vascular Tumor Formation by the Acyclic Nucleoside Phosphonate Cidofovir Cancer Res., July 1, 2001; 61(13): 5057 - 5064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. A. de Vrueh, E. T. Rump, E. van de Bilt, R. van Veghel, J. Balzarini, E. A. L. Biessen, T. J. C. van Berkel, and M. K. Bijsterbosch Carrier-Mediated Delivery of 9-(2-Phosphonylmethoxyethyl)Adenine to Parenchymal Liver Cells: a Novel Therapeutic Approach for Hepatitis B Antimicrob. Agents Chemother., March 1, 2000; 44(3): 477 - 483. [Abstract] [Full Text]
|
|
|
|
|
|
J. Bedard, S. May, M. Lis, L. Tryphonas, J. Drach, J. Huffman, R. Sidwell, L. Chan, T. Bowlin, and R. Rando Comparative Study of the Anti-Human Cytomegalovirus Activities and Toxicities of a Tetrahydrofuran Phosphonate Analogue of Guanosine and Cidofovir Antimicrob. Agents Chemother., March 1, 1999; 43(3): 557 - 567. [Abstract] [Full Text]
|
|
|
|
|
|
J. Neyts and E. De Clercq In Vitro and In Vivo Inhibition of Murine Gamma Herpesvirus 68 Replication by Selected Antiviral Agents Antimicrob. Agents Chemother., January 1, 1998; 42(1): 170 - 172. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. A. Jacobson Treatment of Cytomegalovirus Retinitis in Patients with the Acquired Immunodeficiency Syndrome N. Engl. J. Med., July 10, 1997; 337(2): 105 - 114. [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
